Proprotein Convertases Subtilisin/Kexin Type 9, an enzyme turned escort protein: Hepatic and extra hepatic functions

Journal of Diabetes

Volumn 5, Issue 4, 2013, Pages 391-405

  Mbikay, Majambu ^a,b,c   Mayne, Janice ^b   Chrétien, Michel ^a,b,c,d  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

Cardiovascular disease; Cholesterolemia; Genetic polymorphisms; Lipoproteins; Proprotein Convertases Subtilisin Kexin Type 9

Indexed keywords

BIOLOGICAL MARKER; KEXIN TYPE 9; LOW DENSITY LIPOPROTEIN RECEPTOR; SUBTILISIN; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; BIOCHEMISTRY; CHOLESTEROL BLOOD LEVEL; GENETIC VARIABILITY; HYPERCHOLESTEROLEMIA; LIVER FUNCTION; MOLECULAR BIOLOGY; PRIORITY JOURNAL; REVIEW;

CARDIOVASCULAR DISEASE; CHOLESTEROLEMIA; GENETIC POLYMORPHISMS; LIPOPROTEINS; PROPROTEIN CONVERTASES SUBTILISIN/KEXIN TYPE 9;

AMINO ACID SEQUENCE; ANIMALS; BIOLOGICAL TRANSPORT; HUMANS; LIVER; MOLECULAR SEQUENCE DATA; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES;

EID: 84887018396     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/1753-0407.12064     Document Type: Review

References (174)

1. Seidah NG, Benjannet S, Wickham L etal. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A. 2003; 100: 928-933.
2. Lambert G, Sjouke B, Choque B, Kastelein JJ, Hovingh GK. The PCSK9 decade. J Lipid Res. 2012; 53: 2515-2524.
3. Abifadel M, Varret M, Rabes JP etal. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003; 34: 154-156.
4. Cohen JC, Boerwinkle E, Mosley TH, Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006; 354: 1264-1272.
5. Attie AD. The mystery of PCSK9. Arterioscler Thromb Vasc Biol. 2004; 24: 1337-1339.
6. Lambert G, Krempf M, Costet P. PCSK9: A promising therapeutic target for dyslipidemias? Trends Endocrinol Metab. 2006; 17: 79-81.
7. Horton JD, Cohen JC, Hobbs HH. Molecular biology of PCSK9: Its role in LDL metabolism. Trends Biochem Sci. 2007; 32: 71-77.
8. Costet P, Krempf M, Cariou B. PCSK9 and LDL cholesterol: Unravelling the target to design the bullet. Trends Biochem Sci. 2008; 33: 426-434.
9. Lopez D. PCSK9: An enigmatic protease. Biochim Biophys Acta. 2008; 1781: 184-191.
10. Peterson AS, Fong LG, Young SG. PCSK9 function and physiology. J Lipid Res. 2008; 49: 1595-1599.
11. Hedrick JA. Targeting PCSK9 for the treatment of hypercholesterolemia. Curr Opin Investig Drugs. 2009; 10: 938-946.
12. Horton JD, Cohen JC, Hobbs HH. PCSK9: A convertase that coordinates LDL catabolism. J Lipid Res. 2009; 50 (Suppl.): S172-177.
13. Li H, Ziegler N, Cui R, Liu J. Recent patents on PCSK9: A new target for treating hypercholesterolemia. Recent Pat DNA Gene Seq. 2009; 3: 201-212.
14. Seidah NG. PCSK9 as a therapeutic target of dyslipidemia. Expert Opin Ther Targets. 2009; 13: 19-28.
15. Cariou B, Le May C, Costet P. Clinical aspects of PCSK9. Atherosclerosis. 2011; 216: 258-265.
16. Duff CJ, Hooper NM. PCSK9: An emerging target for treatment of hypercholesterolemia. Expert Opin Ther Targets. 2011; 15: 157-168.
17. Basak A, Palmer-Smith H, Mishra P. Proprotein convertase subtilisin kexin9 (PCSK9): A novel target for cholesterol regulation. Protein Pept Lett. 2012; 19: 575-585.
18. Hooper AJ, Burnett JR. Anti-PCSK9 therapies for the treatment of hypercholesterolemia. Expert Opin Biol Ther. 2013; 13: 429-435.
19. Maxwell KN, Breslow JL. Antibodies to PCSK9: A superior way to lower LDL cholesterol? Circ Res. 2012; 111: 274-277.
20. Mbikay M, Seidah NG (eds). Proprotein Convertases. Humana Press, New York, 2011.
21. Chretien M. My road to Damascus: How I converted to the prohormone theory and the proprotein convertases. Biochem Cell Biol. 2012; 90: 750-768.
22. Copley SD. Moonlighting is mainstream: Paradigm adjustment required. Bioessays. 2012; 34: 578-588.
23. Jeffery CJ. Moonlighting proteins: Old proteins learning new tricks. Trends Genet. 2003; 19: 415-417.
24. Seidah NG. The proprotein convertases, 20 years later. Methods Mol Biol. 2011; 768: 23-57.
25. Seidah NG, Chretien M. Proprotein and prohormone convertases: A family of subtilases generating diverse bioactive polypeptides. Brain Res. 1999; 848: 45-62.
26. Toure BB, Munzer JS, Basak A etal. Biosynthesis and enzymatic characterization of human SKI-1/S1P and the processing of its inhibitory prosegment. J Biol Chem. 2000; 275: 2349-2358.
27. Cheng D, Espenshade PJ, Slaughter CA, Jaen JC, Brown MS, Goldstein JL. Secreted site-1 protease cleaves peptides corresponding to luminal loop of sterol regulatory element-binding proteins. J Biol Chem. 1999; 274: 805-812.
28. Espenshade PJ, Cheng D, Goldstein JL, Brown MS. Autocatalytic processing of site-1 protease removes propeptide and permits cleavage of sterol regulatory element-binding proteins. J Biol Chem. 1999; 274: 795-804.
29. Pullikotil P, Vincent M, Nichol ST, Seidah NG. Development of protein-based inhibitors of the proprotein of convertase SKI-1/S1P: Processing of SREBP-2, ATF6 and a viral glycoprotein. J Biol Chem. 2004; 279: 338-347.
30. Ye J, Rawson RB, Komuro R etal. ER stress induces cleavage of membrane-bound ATF6 by the same proteases that process SREBPs. Mol Cell. 2000; 6: 1355-1364.
31. Mbikay M, Tadros H, Ishida N etal. Impaired fertility in mice deficient for the testicular germ-cell protease PC4. Proc Natl Acad Sci U S A. 1997; 94: 6842-6846.
32. Gyamera-Acheampong C, Mbikay M. Proprotein convertase subtilisin/kexin type 4 in mammalian fertility: A review. Hum Reprod Update. 2009; 15: 237-247.
33. Roebroek AJ, Umans L, Pauli IG etal. Failure of ventral closure and axial rotation in embryos lacking the proprotein convertase Furin. Development. 1998; 125: 4863-4876.
34. Essalmani R, Hamelin J, Marcinkiewicz J etal. Deletion of the gene encoding proprotein convertase 5/6 causes early embryonic lethality in the mouse. Mol Cell Biol. 2006; 26: 354-361.
35. Constam DB, Robertson EJ. SPC4/PACE4 regulates a TGFbeta signaling network during axis formation. Genes Dev. 2000; 14: 1146-1155.
36. Yang J, Goldstein JL, Hammer RE, Moon YA, Brown MS, Horton JD. Decreased lipid synthesis in livers of mice with disrupted Site-1 protease gene. Proc Natl Acad Sci U S A. 2001; 98: 13607-13612.
37. Zhu X, Zhou A, Dey A etal. Disruption of PC1/3 expression in mice causes dwarfism and multiple neuroendocrine peptide processing defects. Proc Natl Acad Sci U S A. 2002; 99: 10293-10298.
38. Mbikay M, Croissandeau G, Sirois F etal. A targeted deletion/insertion in the mouse Pcsk1 locus is associated with homozygous embryo preimplantation lethality, mutant allele preferential transmission and heterozygous female susceptibility to dietary fat. Dev Biol. 2007; 306: 584-598.
39. Anini Y, Mayne J, Gagnon J etal. Genetic deficiency for proprotein convertase subtilisin/kexin type 2 in mice is associated with decreased adiposity and protection from dietary fat-induced body weight gain. Int J Obes. 2010; 34: 1599-1607.
40. Mbikay M, Sirois F, Mayne J etal. PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities. FEBS Lett. 2010; 584: 701-706.
41. Furuta M, Yano H, Zhou A etal. Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2. Proc Natl Acad Sci U S A. 1997; 94: 6646-6651.
42. Benjannet S, Rhainds D, Essalmani R etal. NARC-1/PCSK9 and its natural mutants: Zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem. 2004; 279: 865-875.
43. Maxwell KN, Breslow JL. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci U S A. 2004; 101: 7100-7105.
44. Seidah NG, Prat A. The proprotein convertases are potential targets in the treatment of dyslipidemia. J Mol Med. 2007; 85: 685-696.
45. Croissandeau G, Wahnon F, Yashpal K etal. Increased stress-induced analgesia in mice lacking the proneuropeptide convertase PC2. Neurosci Lett. 2006; 406: 71-75.
46. Besnard J, Ruda GF, Setola V etal. Automated design of ligands to polypharmacological profiles. Nature. 2012; 492: 215-220.
47. Khatib AM, Siegfried G, Prat A etal. Inhibition of proprotein convertases is associated with loss of growth and tumorigenicity of HT-29 human colon carcinoma cells: Importance of insulin-like growth factor-1 (IGF-1) receptor processing in IGF-1-mediated functions. J Biol Chem. 2001; 276: 686-693.
48. Stawowy P, Fleck E. Proprotein convertases furin and PC5: Targeting atherosclerosis and restenosis at multiple levels. J Mol Med. 2005; 83: 865-875.
49. Vollenweider F, Benjannet S, Decroly E etal. Comparative cellular processing of the human immunodeficiency virus (HIV-1) envelope glycoprotein gp160 by the mammalian subtilisin/kexin-like convertases. Biochem J. 1996; 314 (Pt 2): 521-532.
50. Stieneke-Gröber A, Vey M, Angliker H etal. Influenza virus hemagglutinin with multibasic cleavage site is activated by furin, a subtilisin-like endoprotease. EMBO J. 1992; 11: 2407-2414.
51. Kido H, Okumura Y, Takahashi E etal. Host envelope glycoprotein processing proteases are indispensable for entry into human cells by seasonal and highly pathogenic avian influenza viruses. J Mol Genet Med. 2008; 3: 167-175.
52. Lenz O, Meulen J, Feldmann H, Klenk HD, Garten W. Identification of a novel consensus sequence at the cleavage site of the Lassa virus glycoprotein. J Virol. 2000; 74: 418-421.
53. Pasquato A, Pullikotil P, Asselin MC etal. The proprotein convertase SKI-1/S1P. In vitro analysis of Lassa virus glycoprotein-derived substrates and ex vivo validation of irreversible peptide inhibitors. J Biol Chem. 2006; 281: 23471-23481.
54. Klimpel KR, Molloy SS, Thomas G, Leppla SH. Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin. Proc Natl Acad Sci U S A. 1992; 89: 10277-10281.
55. Tsuneoka M, Nakayama K, Hatsuzawa K, Komada M, Kitamura N, Mekada E. Evidence for involvement of furin in cleavage and activation of diphtheria toxin. J Biol Chem. 1993; 268: 26461-26465.
56. Chiron MF, Fryling CM, FitzGerald DJ. Cleavage of pseudomonas exotoxin and diphtheria toxin by a furin-like enzyme prepared from beef liver. J Biol Chem. 1994; 269: 167-176.
57. Garred O, van Deurs B, Sandvig K. Furin-induced cleavage and activation of Shiga toxin. J Biol Chem. 1995; 270: 10817-10821.
58. Gordon VM, Klimpel KR, Arora N, Henderson MA, Leppla SH. Proteolytic activation of bacterial toxins by eukaryotic cells is performed by furin and by additional cellular proteases. Infect Immun. 1995; 63: 82-87.
59. Abrami L, Fivaz M, Decroly E etal. The pore-forming toxin proaerolysin is activated by furin. J Biol Chem. 1998; 273: 656-661.
60. Chretien M, Mbikay M, Gaspar L, Seidah NG. Proprotein convertases and the pathophysiology of human diseases: Prospective considerations. Proc Assoc Am Physicians. 1995; 107: 47-66.
61. Senzer N, Barve M, Kuhn J etal. Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer. Mol Ther. 2012; 20: 679-686.
62. Nie G, Li Y, Wang M, Liu YX, Findlay JK, Salamonsen LA. Inhibiting uterine PC6 blocks embryo implantation: An obligatory role for a proprotein convertase in fertility. Biol Reprod. 2005; 72: 1029-1036.
63. Heng S, Hannan NJ, Rombauts LJ, Salamonsen LA, Nie G. PC6 levels in uterine lavage are closely associated with uterine receptivity and significantly lower in a subgroup of women with unexplained infertility. Hum Reprod. 2011; 26: 840-846.
64. Couture F, D'Anjou F, Desjardins R, Boudreau F, Day R. Role of proprotein convertases in prostate cancer progression. Neoplasia. 2012; 14: 1032-1042.
65. Kohli P, Desai NR, Giugliano RP etal. Design and rationale of the LAPLACE-TIMI 57 trial: A phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy. Clin Cardiol. 2012; 35: 385-391.
66. Milazzo L, Antinori S. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med. 2012; 366: 2425-2426.
67. Stein EA, Gipe D, Bergeron J etal. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: A phase 2 randomised controlled trial. Lancet. 2012; 380: 29-36.
68. Stein EA, Mellis S, Yancopoulos GD etal. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med. 2012; 366: 1108-1118.
69. Sullivan D, Olsson AG, Scott R etal. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: The GAUSS randomized trial. J Am Med Assoc. 2012; 308: 2497-2506.
70. Zaid A, Roubtsova A, Essalmani R etal. Proprotein convertase subtilisin/kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology. 2008; 48: 646-654.
71. Mayne J, Dewpura T, Raymond A etal. Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture. Clin Chem. 2011; 57: 1415-1423.
72. Benjannet S, Hamelin J, Chretien M, Seidah NG. Loss- and gain-of-function PCSK9 variants: Cleavage specificity, dominant negative effects, and low density lipoprotein receptor (LDLR) degradation. J Biol Chem. 2012; 287: 745-755.
73. Dewpura T, Raymond A, Hamelin J etal. PCSK9 is phosphorylated by a Golgi casein kinase-like kinase ex vivo and circulates as a phosphoprotein in humans. FEBS J. 2008; 275: 3480-3493.
74. Benjannet S, Rhainds D, Hamelin J, Nassoury N, Seidah NG. The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: Functional consequences of natural mutations and post-translational modifications. J Biol Chem. 2006; 281: 30561-30572.
75. Essalmani R, Susan-Resiga D, Chamberland A etal. In vivo evidence that furin from hepatocytes inactivates PCSK9. J Biol Chem. 2011; 286: 4257-4263.
76. Piper DE, Jackson S, Liu Q etal. The crystal structure of PCSK9: A regulator of plasma LDL-cholesterol. Structure. 2007; 15: 545-552.
77. Hampton EN, Knuth MW, Li J, Harris JL, Lesley SA, Spraggon G. The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain. Proc Natl Acad Sci U S A. 2007; 104: 604-609.
78. Kourimate S, Chetiveaux M, Jarnoux AL, Lalanne F, Costet P. Cellular and secreted pro-protein convertase subtilisin/kexin type 9 catalytic activity in hepatocytes. Atherosclerosis. 2009; 206: 134-140.
79. Naureckiene S, Ma L, Sreekumar K etal. Functional characterization of Narc 1, a novel proteinase related to proteinase K. Arch Biochem Biophys. 2003; 420: 55-67.
80. Zhang DW, Lagace TA, Garuti R etal. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem. 2007; 282: 602-612.
81. Yamamoto T, Lu C, Ryan RO. A two-step binding model of PCSK9 interaction with the low density lipoprotein receptor. J Biol Chem. 2011; 286: 5464-5470.
82. Zhang DW, Garuti R, Tang WJ, Cohen JC, Hobbs HH. Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor. Proc Natl Acad Sci U S A. 2008; 105: 45-50.
83. Ni YG, Condra JH, Orsatti L etal. A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake. J Biol Chem. 2010; 285: 882-891.
84. Lo Surdo P, Bottomley MJ, Calzetta A etal. Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH. EMBO Rep. 2011; 12: 1300-1305.
85. Benjannet S, Saavedra YG, Hamelin J etal. Effects of the prosegment and pH on the activity of PCSK9: Evidence for additional processing events. J Biol Chem. 2010; 285: 965-978.
86. Fisher TS, Lo Surdo P, Pandit S etal. Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation. J Biol Chem. 2007; 282: 502-512.
87. Holla OL, Laerdahl JK, Strom TB etal. Removal of acidic residues of the prodomain of PCSK9 increases its activity towards the LDL receptor. Biochem Biophys Res Commun. 2011; 406: 234-238.
88. Holla OL, Cameron J, Tveten K etal. Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors. J Lipid Res. 2011; 52: 1787-1794.
89. Du F, Hui Y, Zhang M, Linton MF, Fazio S, Fan D. Novel domain interaction regulates secretion of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein. J Biol Chem. 2011; 286: 054-61.
90. Luna Saavedra YG, Day R, Seidah NG. The M2 Module of the Cys-His-rich Domain (CHRD) of PCSK9 protein is needed for the extracellular low-density lipoprotein receptor (LDLR) degradation pathway. J Biol Chem. 2012; 287: 492-501.
91. Poirier S, Mayer G, Poupon V etal. Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: Evidence for an intracellular route. J Biol Chem. 2009; 284: 856-864.
92. Nassoury N, Blasiole DA, Tebon Oler A etal. The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR. Traffic. 2007; 8: 718-732.
93. Ai X, Fischer P, Palyha OC etal. Utilizing HaloTag technology to track the fate of PCSK9 from intracellular vs. extracellular sources. Curr Chem Genomics. 2012; 6: 38-47.
94. Lagace TA, Curtis DE, Garuti R etal. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic mice. J Clin Invest. 2006; 116: 2995-3005.
95. Cameron J, Holla OL, Ranheim T, Kulseth MA, Berge KE, Leren TP. Effect of mutations in the PCSK9 gene on the cell surface LDL receptors. Hum Mol Genet. 2006; 15: 1551-1558.
96. Devay RM, Shelton DL, Liang H. Characterization of PCSK9 trafficking reveals a novel lysosomal targeting mechanism via APLP2. J Biol Chem. 2013; 288: 805.
97. Grieve AG, Moss SE, Hayes MJ. Annexin A2 at the interface of actin and membrane dynamics: A focus on its roles in endocytosis and cell polarization. Int J Cell Biol. 2012; 2012: 430.
98. Mayer G, Poirier S, Seidah NG. Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels. J Biol Chem. 2008; 283: 791.
99. Seidah NG, Poirier S, Denis M etal. Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation. PLoS One. 2012; 7: e41865.
100. Lipari MT, Li W, Moran P etal. Furin-cleaved proprotein convertase Subtilisin/Kexin Type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels. J Biol Chem. 2012; 287: 482-491.
101. Dong W, Fricker LD, Day R. Carboxypeptidase D is a potential candidate to carry out redundant processing functions of carboxypeptidase E based on comparative distribution studies in the rat central nervous system. Neuroscience. 1999; 89: 1301-1317.
102. Poirier S, Mayer G, Benjannet S etal. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem. 2008; 283: 2363-2372.
103. Liu M, Wu G, Baysarowich J etal. PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain. J Lipid Res. 2010; 51: 2611-2618.
104. Roubtsova A, Munkonda MN, Awan Z etal. Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue. Arterioscler Thromb Vasc Biol. 2011; 31: 785-791.
105. Kysenius K, Muggalla P, Matlik K, Arumae U, Huttunen HJ. PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling. Cell Mol Life Sci. 2012; 69: 1903-1916.
106. Sun H, Samarghandi A, Zhang N, Yao Z, Xiong M, Teng BB. Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor. Arterioscler Thromb Vasc Biol. 2012; 32: 1585-1595.
107. Jonas MC, Costantini C, Puglielli L. PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1. EMBO Rep. 2008; 9: 916-922.
108. Kellenberger S, Schild L. Epithelial sodium channel/degenerin family of ion channels: A variety of functions for a shared structure. Physiol Rev. 2002; 82: 735-767.
109. Sharotri V, Collier DM, Olson DR, Zhou R, Snyder PM. Regulation of epithelial sodium channel trafficking by proprotein convertase subtilisin/kexin type 9 (PCSK9). J Biol Chem. 2012; 287: 266-274.
110. Labonte P, Begley S, Guevin C etal. PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression. Hepatology. 2009; 50: 17-24.
111. Brown MS, Goldstein JL. Lipoprotein receptors in the liver. Control signals for plasma cholesterol traffic. J Clin Invest. 1983; 72: 743-747.
112. Maxwell KN, Fisher EA, Breslow JL. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc Natl Acad Sci U S A. 2005; 102: 2069-2074.
113. Rashid S, Curtis DE, Garuti R etal. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci U S A. 2005; 102: 5374-5379.
114. Park SW, Moon YA, Horton JD. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J Biol Chem. 2004; 279: 630-638.
115. Lalanne F, Lambert G, Amar MJ etal. Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells. J Lipid Res. 2005; 46: 1312-1319.
116. Lambert G, Jarnoux AL, Pineau T etal. Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: Lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor. Endocrinology. 2006; 147: 4985-4995.
117. Chernogubova E, Strawbridge R, Mahdessian H etal. Common and low-frequency genetic variants in the PCSK9 locus influence circulating PCSK9 levels. Arterioscler Thromb Vasc Biol. 2012; 32: 1526-1534.
118. Zhao Z, Tuakli-Wosornu Y, Lagace TA etal. Molecular Characterization of Loss-of-Function Mutations in PCSK9 and Identification of a Compound Heterozygote. Am J Hum Genet. 2006; 79: 514-523.
119. Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005; 37: 161-165.
120. Kotowski IK, Pertsemlidis A, Luke A etal. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Hum Genet. 2006; 78: 410-422.
121. Leren TP. Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia. Clin Genet. 2004; 65: 419-422.
122. Allard D, Amsellem S, Abifadel M etal. Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia. Hum Mutat. 2005; 26: 497-506.
123. Homer VM, Marais AD, Charlton F etal. Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa. Atherosclerosis. 2008; 196: 659-666.
124. Mayne J, Ooi TC, Raymond A etal. Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations. Lipids Health Dis. 2013; 12: 70.
125. Kathiresan S, Melander O, Guiducci C etal. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet. 2008; 40: 189-197.
126. Willer CJ, Sanna S, Jackson AU etal. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet. 2008; 40: 161-169.
127. Chasman DI, Pare G, Zee RY etal. Genetic loci associated with plasma concentration of low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein A1, and Apolipoprotein B among 6382 white women in genome-wide analysis with replication. Circ Cardiovasc Genet. 2008; 1: 21-30.
128. Wu Y, Waite LL, Jackson AU etal. Trans-ethnic fine-mapping of lipid Loci identifies population-specific signals and allelic heterogeneity that increases the trait variance explained. PLoS Genet. 2013; 9: e1003379.
129. Grupping AY, Cnop M, Van Schravendijk CF, Hannaert JC, Van Berkel TJ, Pipeleers DG. Low density lipoprotein binding and uptake by human and rat islet beta cells. Endocrinology. 1997; 138: 4064-4068.
130. Cnop M, Grupping A, Hoorens A, Bouwens L, Pipeleers-Marichal M, Pipeleers D. Endocytosis of low-density lipoprotein by human pancreatic beta cells and uptake in lipid-storing vesicles, which increase with age. Am J Pathol. 2000; 156: 237-244.
131. Rutti S, Ehses JA, Sibler RA etal. Low- and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic beta-cells. Endocrinology. 2009; 150: 4521-4530.
132. Sun K, Kusminski CM, Scherer PE. Adipose tissue remodeling and obesity. J Clin Invest. 2011; 121: 2094-2101.
133. Ferri N, Tibolla G, Pirillo A etal. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. Atherosclerosis. 2012; 220: 381-386.
134. Lee CJ, Lee YH, Park SW etal. Association of serum proprotein convertase subtilisin/kexin type 9 with carotid intima media thickness in hypertensive subjects. Metabolism. 2013; 62: 845-850.
135. Le Bras M, Roquilly A, Deckert V etal. Plasma PCSK9 is a late biomarker of severity in patients with severe trauma injury. J Clin Endocrinol Metab. 2013; 98: E732-736.
136. Kwakernaak AJ, Lambert G, Slagman MC etal. Proprotein convertase subtilisin-kexin type 9 is elevated in proteinuric subjects: Relationship with lipoprotein response to antiproteinuric treatment. Atherosclerosis. 2013; 226: 459-465.
137. Miyazawa H, Honda T, Miyauchi S etal. Increased serum PCSK9 concentrations are associated with periodontal infection but do not correlate with LDL cholesterol concentration. Clin Chim Acta. 2012; 413: 154-159.
138. Chrétien M, Seidah NG, Basak A, Mbikay M. Proprotein convertases as therapeutic targets. Expert Opin Ther Targets. 2008; 12: 1289-1300.
139. Seidah NG, Prat A. The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov. 2012; 11: 367-383.
140. Lopez D. Inhibition of PCSK9 as a novel strategy for the treatment of hypercholesterolemia. Drug News Perspect. 2008; 21: 323-330.
141. Graham MJ, Lemonidis KM, Whipple CP etal. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J Lipid Res. 2007; 48: 763-767.
142. Frank-Kamenetsky M, Grefhorst A, Anderson NN etal. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A. 2008; 105: 915-920.
143. Gupta N, Fisker N, Asselin MC etal. A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo. PLoS One. 2010; 5: e10682.
144. Lindholm MW, Elmen J, Fisker N etal. PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates. Mol Ther. 2012; 20: 376-381.
145. Yamamoto T, Harada-Shiba M, Nakatani M etal. Cholesterol-lowering Action of BNA-based Antisense Oligonucleotides Targeting PCSK9 in Atherogenic Diet-induced Hypercholesterolemic Mice. Mol Ther Nucleic Acids. 2012; 1: e22.
146. Chan JC, Piper DE, Cao Q etal. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci U S A. 2009; 106: 9820-9825.
147. Chaparro-Riggers J, Liang H, DeVay RM etal. Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9. J Biol Chem. 2012; 287: 90-97.
148. Zhang L, McCabe T, Condra JH etal. An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes. Int J Biol Sci. 2012; 8: 310-327.
149. Raal F, Scott R, Somaratne R etal. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: The reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial. Circulation. 2012; 126: 2408-2417.
150. van Poelgeest EP, Swart RM, Betjes MG etal. Acute kidney injury during therapy with an antisense oligonucleotide directed against PCSK9. Am J Kidney Dis. 2013; pii: S0272-6386(13)00556-8. doi: 10.1053/j.ajkd.2013.02.359. [Epub ahead of print].
151. Seidah NG. Proprotein Convertase Subtilisin Kexin 9 (PCSK9) inhibitors in the treatment of hypercholesterolemia and other pathologies. Curr Pharm Des. 2013; 19: 3161-3172.
152. Calza L, Manfredi R, Chiodo F. Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART. Aids. 2003; 17: 851-859.
153. Beltowski J, Wojcicka G, Jamroz-Wisniewska A. Adverse effects of statins - mechanisms and consequences. Curr Drug Saf. 2009; 4: 209-228.
154. Dubuc G, Chamberland A, Wassef H etal. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2004; 24: 1454-1459.
155. Mayne J, Dewpura T, Raymond A etal. Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. Lipids Health Dis. 2008; 7: 22.
156. Awan Z, Seidah NG, MacFadyen JG etal. Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: The JUPITER trial. Clin Chem. 2012; 58: 183-189.
157. Berthold HK, Seidah NG, Benjannet S, Gouni-Berthold I. Evidence from a randomized trial that simvastatin, but not ezetimibe, upregulates circulating PCSK9 levels. PLoS One. 2013; 8: e60095.
158. Liang H, Chaparro-Riggers J, Strop P etal. Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates. J Pharmacol Exp Ther. 2012; 340: 228-236.
159. Berge KE, Ose L, Leren TP. Missense mutations in the PCSK9 Gene are associated with hypocholesterolemia and possibly increased response to statin therapy. Arterioscler Thromb Vasc Biol. 2006; 26: 1094-1100.
160. Pisciotta L, Sallo R, Rabacchi C, Wunsch A, Calandra S, Bertolini S. Leucine 10 allelic variant in signal peptide of PCSK9 increases the LDL cholesterol-lowering effect of statins in patients with familial hypercholesterolaemia. Nutr Metab Cardiovasc Dis. 2012; 22: 831-835.
161. Thompson JF, Hyde CL, Wood LS etal. Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort. Circ Cardiovasc Genet. 2009; 2: 173-181.
162. Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med. 2012; 367: 1891-1900.
163. Hooper AJ, Marais AD, Tanyanyiwa DM, Burnett JR. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis. 2007; 193: 445-448.
164. Sirois F, Gbeha E, Sanni A, Chretien M, Labuda D, Mbikay M. Ethnic differences in the frequency of the cardioprotective C679X PCSK9 mutation in a West African population. Genet Test. 2008; 12: 377-380.
165. Chen SN, Ballantyne CM, Gotto AM, Jr, Tan Y, Willerson JT, Marian AJ. A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. J Am Coll Cardiol. 2005; 45: 1611-1619.
166. Yue P, Averna M, Lin X, Schonfeld G. The c.43_44insCTG variation in PCSK9 is associated with low plasma LDL-cholesterol in a Caucasian population. Hum Mutat. 2006; 27: 460-466.
167. Miyake Y, Kimura R, Kokubo Y etal. Genetic variants in PCSK9 in the Japanese population: Rare genetic variants in PCSK9 might collectively contribute to plasma LDL cholesterol levels in the general population. Atherosclerosis. 2008; 196: 29-36.
168. Ding K, McDonough SJ, Kullo IJ. Evidence for positive selection in the C-terminal domain of the cholesterol metabolism gene PCSK9 based on phylogenetic analysis in 14 primate species. PLoS ONE. 2007; 2: e1098.
169. Ding K, Kullo IJ. Molecular population genetics of PCSK9: A signature of recent positive selection. Pharmacogenet Genomics. 2008; 18: 169-179.
170. Mbikay M, Mayne J, Seidah NG, Chretien M. Of PCSK9, cholesterol homeostasis and parasitic infections: Possible survival benefits of loss-of-function PCSK9 genetic polymorphisms. Med Hypotheses. 2007; 69: 1010-1017.
171. Ghosh S, Sengupta A, Sharma S, Sonawat HM. Metabolic fingerprints of serum, brain, and liver are distinct for mice with cerebral and noncerebral malaria: A (1)h NMR spectroscopy-based metabonomic study. J Proteome Res. 2012; 11: 4992-5004.
172. Reis PA, Estato V, da Silva TI etal. Statins decrease neuroinflammation and prevent cognitive impairment after cerebral malaria. PLoS Pathog. 2012; 8: e1003099.
173. Taoufiq Z, Pino P, N'Dilimabaka N etal. Atorvastatin prevents Plasmodium falciparum cytoadherence and endothelial damage. Malar J. 2011; 10: 52.
174. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: Part I: General considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001; 104: 2746-2753.